U.S. markets closed

Forte Biosciences, Inc. (FBRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
32.00-2.48 (-7.19%)
At close: 4:00PM EDT

32.00 0.00 (0.00%)
After hours: 5:55PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close34.48
Bid29.35 x 1400
Ask37.44 x 900
Day's Range31.00 - 34.22
52 Week Range13.35 - 53.99
Avg. Volume221,357
Market Cap432.374M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateMay 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est88.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Business Wire

    Forte Biosciences, Inc. to Announce First Quarter 2021 Results and Provide a General Business Update

    Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, will be providing first quarter 2021 results and a general business update on May 10, 2021.

  • Forte Posts Lower-Than-Feared Quarterly Loss; Shares Drop 9.5%

    Forte Posts Lower-Than-Feared Quarterly Loss; Shares Drop 9.5%

    Forte Biosciences reported a smaller-than-expected loss in the fourth quarter. Shares of the clinical-stage biopharmaceutical company rose almost 2% in Wednesday’s extended trading session after closing 9.5% lower on the day. Forte (FBRX) incurred a loss of $0.37 per share in 4Q, compared to the $0.57 loss per share estimated by analysts. Results compared favorably to the prior-year quarter’s loss of $0.74 per share. The company’s research and development expenses more than doubled on a year-over-year basis to $3 million in the quarter, while total general and administrative expenses more than tripled to $1.5 million. (See Forte Biosciences stock analysis on TipRanks) Forte CEO Paul Wagner said, “In September, we initiated a randomized trial of FB-401 in atopic dermatitis patients, including adults and children 2 years of age and older. We are very pleased to announce that patient enrollment is now complete.” “Another notable milestone was the granting of Fast Track designation to FB-401 by the FDA in recognition of the unmet need and seriousness of the disease,” Wagner added. Ladenburg Thalmann analyst Michael Higgins increased the stock’s price target to $90 (260% upside potential) from $70 and maintained a Buy rating “given the increased confidence in FB-401’s Phase 2.” The consensus rating among analysts is a Strong Buy based on 3 unanimous Buys. The average analyst price target stands at $97.50 and implies upside potential of almost 290% to current levels over the next 12 months. Shares have gained 11.2% over the past year. Related News: Ametek Inks Deal To Acquire Abaco Systems For $1.35B IHS Markit’s Quarterly Results Top Analysts’ Expectations; Street Sees 26% Upside ServiceNow Inks Deal To Acquire Intellibot, Boosts Automated Workflow More recent articles from Smarter Analyst: Equifax Snaps Up i2verify; Street Sees 21% Upside Mettler-Toledo Acquires PendoTECH; Street Says Hold Ovintiv Agrees To Sell Eagle Ford Assets For $880 Million, Updates Guidance Celanese To Expand Manufacturing Capacity; Street Says Buy

  • Business Wire

    Forte Biosciences, Inc. Announces 4Q and Full Year 2020 Results and Provides a General Business Update

    Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company announces fourth quarter and full year 2020 results and provides a general business update on March 24, 2021.